mdl 72527 has been researched along with framycetin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cipolla, B; Guillé, F; Havouis, R; Lobel, B; Martin, C; Moulinoux, JP; Quemener, V; Seiler, N | 1 |
| Blanchard, Y; Chamaillard, L; Cipolla, B; Guillé, F; Havouis, R; Moulinoux, JP; Quemener, V | 1 |
2 other study(ies) available for mdl 72527 and framycetin
| Article | Year |
|---|---|
The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation.
Topics: Adenocarcinoma; Animals; Diet; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Eflornithine; Male; Neomycin; Neoplasm Transplantation; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Prostatic Neoplasms; Putrescine; Rats; Rats, Inbred Strains | 1991 |
In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Eflornithine; Lung Neoplasms; Male; Metronidazole; Neomycin; Oxidoreductases Acting on CH-NH Group Donors; Polyamines; Prostatic Neoplasms; Protein Synthesis Inhibitors; Putrescine; Rats; Rats, Inbred Strains; Survival Rate | 1996 |